Navigation Links
Goodwin Biotechnology Announces a Collaboration with Spectros Corporation
Date:10/24/2011

PLANTATION, Fla. and PORTOLA VALLEY, Calif., Oct. 24, 2011 /PRNewswire/ -- Goodwin Biotechnology, Inc. (GBI) and Spectros Corporation jointly announced a collaboration for the process development and cGMP manufacturing of an antibody: dye conjugate that will be used in Phase I and Phase II clinical trials.

"The leading surgical treatment for prostate cancer is prostatectomy, or removal of the prostate," noted David Benaron, CEO at Spectros Corporation. "Unfortunately, residual tumor remains at the edge of surgery about 30% of the time, leading to a significantly higher risk of local recurrence of the cancer and higher rates of death. By collaborating with GBI on the conjugation of a fluorescent dye and a monoclonal antibody that has a high level of affinity with the prostate-specific membrane antigen, we aim to identify and minimize the residual tumor, thereby reducing the number of people who have to receive additional treatment such as high doses of radiation. This type of cancer detection, called Molecular Imaging, may represent an important advance in cancer by improving the diagnosis, individualized treatment selection and monitoring, and even survival. We look forward to clinical trials with this agent, ProstaFluor®, beginning next year."

"We're excited about the opportunity to contribute a decade of bioconjugation experience to this important project," said Muctarr Sesay, PhD, Vice President of Process Development at GBI. "The potential of this innovative approach may represent a new paradigm in the way patients are diagnosed and treated, and contribute significantly to the quality of life of those affected by this insidious disease."

About Goodwin Biotechnology, Inc.Goodwin Biotechnology is a fully integrated cGMP contract manufacturer of monoclonal antibodies, recombinant proteins and vaccines. GBI has the expertise and experience in cell line development, process development and GMP manufacturing of recombinant proteins and antibodies, as well as conjugated therapeutic proteins (e.g., antibodies conjugated to linkers for radioimmune therapy and diagnostics, other antibodies, proteins, chemotoxins, or plant toxins) by leveraging our proprietary conjugation technology. By working with GBI, our clients can enhance the value of their product candidates with clear development and manufacturing strategies and a road map to meet product requirements from the milligram, gram and kilogram range as the product candidates move along the clinical approval pathway. With nearly 20 years of experience as an independent contract manufacturer, GBI has worked with companies of all sizes from small university spin-offs to major research institutes, government agencies and large, established biopharmaceutical companies.

About Spectros CorporationSpectros Corporation makes advanced molecular sensing and imaging devices which shed light on life-threatening diseases, including ischemia and cancer. The company's champion product, the T-Stat® broadband Tissue Oximeter, was the first medical device FDA-approved as sensitive to ischemia, an insufficient supply of oxygen to tissue. Spectros also develops molecular diagnostic tools for breast and prostate cancer, including the ProstaFluor® contrast agent described herein. Spectros is a venture-supported private concern and markets its products in the U.S. and internationally.For more information, please contact:Goodwin Biotechnology:Spectros Corporation:Dave Cunningham

Ms. Elizabeth van Thillo-RohlffDirector of Business Development

Director, Marketing and SalesPhone: (954) 327-9639

Phone: 650-529-2865Email: DCunningham@GoodwinBio.com

Email: info@spectros.com
'/>"/>

SOURCE Goodwin Biotechnology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Goodwin Biotechnology Announces a Collaboration With Alethia Biotherapeutics
2. Goodwin Biotechnology Announces Signing New Biopharmaceutical Development & Manufacturing Agreement
3. HUYA Bioscience International and Tianjin International Joint Academy of Biotechnology and Medicine Form Alliance
4. The Patent Board, IP Tracking and Analysis Firm, Ranks Heskas Science Strength in Biotechnology Industry Top 50
5. Puma Biotechnology Announces Licensing Agreement with Pfizer for the Development and Commercialization of Neratinib, an Investigational Pan-HER Inhibitor; Closes $55 Million Private Placement and Completes Merger
6. Top 450 Biotechnology (Pharmaceuticals) Report (Global)
7. STELARA® Awarded 2011 Prix Galien USA in Best Biotechnology Product Category
8. 2011 Prix Galien USA Final Candidates Announced: Competing for Best Biotechnology Product and Best Pharmaceutical Agent
9. Lilly Announces New Investment to Further Boost Its Biotechnology Capabilities
10. Generex Biotechnology Corporation CEO Presentation Now Available for On-Demand Viewing at RetailInvestorConferences.com
11. Generex Biotechnology Corporation CEO to Present Live, Online at RetailInvestorConferences.com on May 5th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... June 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as ... Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) ... Daylight Time). As previously announced on May ... definitive merger agreement under which Jazz Pharmaceuticals has commenced ...
(Date:6/26/2016)... -- Story Highlights: , ... health care industry is causing providers to review operating ... offers a suite of solutions for health care providers ... optimization: labor resource analysis, revenue cycle optimization and physician ... and better economics ...
(Date:6/24/2016)... 24, 2016  Collagen Matrix, Inc., ("Collagen Matrix") ... manufacturing of collagen and mineral based medical devices ... Bill Messer has joined the company ... leverage the growing portfolio of oral surgery, neurosurgery, ... Bill joins the Collagen Matrix executive team as ...
Breaking Medicine Technology:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
(Date:6/24/2016)... Rhinebeck, NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of ... of companies that call for a minimum wage raise to $12 an hour by 2020 ... wage. This will restore the lost value of the minimum wage, assure the wage floor ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations at ... Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete ...
Breaking Medicine News(10 mins):